Clinical Trials
84 trialsBOLSTER
Lisata Therapeutics, Inc.
Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer
NRG Oncology
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Hutchmed
MAST
Imugene Limited
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Peking University
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
Mayo Clinic
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
University of Washington
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
TriSalus Life Sciences, Inc.
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
FIGHT-302
Incyte Corporation
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Eli Lilly and Company
First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC
Shandong Cancer Hospital and Institute
SIRCCA
Sirtex Medical
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
Kinnate Biopharma
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors
The First Affiliated Hospital with Nanjing Medical University
LT for iCCA
University Health Network, Toronto
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
ABM Therapeutics Shanghai Company Limited
Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma
Medical University of South Carolina
ICC
University of Alabama at Birmingham
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
University of California, San Diego
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
QED Therapeutics, a BridgeBio company
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Academic and Community Cancer Research United
EPIC
EpicentRx, Inc.
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
EMD Serono
RELEASE
PCI Biotech AS
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
National Institutes of Health Clinical Center (CC)
ALpha-T
Hoffmann-La Roche
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
University of Kentucky
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
QED Therapeutics, a BridgeBio company
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuCana plc
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
Stanford University
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
MOCHA
Sunnybrook Health Sciences Centre
Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer
University of Michigan
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Delcath Systems Inc.
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Washington University School of Medicine
NEOBIL
AIO-Studien-gGmbH